Atomic AI, a San Francisco, CA-based biotechnology firm combining machine studying with structural biology to unlock RNA drug discovery, raised $35M in Collection A funding.
The spherical was led by Playground World, with participation from 8VC, Manufacturing unit HQ, Greylock, NotBoring, AME Cloud Ventures, Nat Friedman, Doug Mohr, Neal Khosla, and Patrick Hsu.
The corporate intends to make use of the funds to speed up progress, develop operations and its enterprise attain.
Led by CEO Raphael Townshend, Atomic AI is a biotechnology firm whose proprietary R&D platform leverages studying basis fashions built-in right into a virtuous cycle with purpose-designed, in-house wet-lab assays, to find and design proprietary 3D RNA structural datasets. Its AI’s proprietary AI-driven 3D RNA construction engine generates RNA structural datasets, integrating machine studying basis fashions with large-scale in-house experimental wet-lab biology to allow the world of RNA drug discovery. Particularly, the know-how can uncover structured, ligandable RNA motifs at pace and accuracy. Past RNA-targeted molecules, the built-in platform may even allow the design of RNA-based medicines and RNA instruments.
The corporate beforehand raised a $7M seed spherical led by 8VC and joined by Greylock, Manufacturing unit HQ, AME Cloud Ventures, AIX Ventures, Xu Ventures, Doug Mohr, Antheia, Inc. CEO Dr. Christina Smolke, and Stanford Bioengineering professor Drew Endy.
FinSMEs
25/01/2023
